The agreement covers a broad group of Pfizer compounds including atorvastatin, doxorubicin, nifedipine and bosutinib, all of which are widely used in pre-clinical research. The Pfizer research compounds and Abcam Biochemicals range will support pre-clinical research in a variety of fields such as neuroscience, cardiovascular disease, cancer and antibiotic resistance.
Steve Roome, General Manager of Abcam Biochemicals, commented: “We are delighted to have signed the licence agreement, and to provide authentic Pfizer compounds to our customers. The compounds are an ideal complement to our current range of exceptional quality small molecules.”
To find out more, please visit www.abcam.com/Pfizer
About Abcam
Abcam plc is a provider of protein research tools and services, with an unrivalled range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and improving the understanding of health and disease.
Abcam is committed to providing scientists with an extensive choice of reagents and tools, with the most comprehensive, honest and up-to-date datasheets and customer reviews, fast delivery and helpful customer service & technical support. The Company’s catalogue evolves with scientific research trends and is growing each year to provide customers with products to meet their research needs. The range now includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam also supports its customers by hosting a range of global scientific events, forums and webinars, providing opportunities for scientists to get together and present their work.
Headquartered in Cambridge, UK, Abcam has global subsidiary offices enabling local services, multi-language support and next-day delivery in over 130 countries. The Company was founded in 1998, and now employs over 680 FTEs. Abcam was admitted to AIM in 2005 (AIM:ABC).
To find out more, please visit www.abcam.com
About Abcam Biochemicals
Abcam Biochemicals, a division of Abcam, offers a range of exceptional quality and high performance bioactive small molecules. The range includes high purity agonists, antagonists, channel blockers, enzyme inhibitors and signaling tools for life science research.
*******
Contacts:
Abcam
Francesca Axe
T: +44 (0) 1223 69600
Media enquiries
Katie Odgaard
Zyme Communications
E: katie.odgaard@zymecommunications.com
T: +44 (0) 7787 502 947
_______________________________________________
Abcam signs licence agreement with Pfizer to supply compounds to researchers
12 June 2013
Abcam Plc., a producer and distributor of high quality protein research tools, announced today that it has entered into a licence agreement with Pfizer. Under the terms of the agreement, Abcam’s Biochemicals division will supply a range of authentic Pfizer compounds for use as pre-clinical research tools by researchers worldwide, alongside the Abcam Biochemicals range of over 2000 bioactive small molecules.